Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

eisa0008_web

China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019 Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …
News

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019 Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …
News
mitigating-burdens-of-tbi

Tranexamic acid to prevent brain bleeds could save thousands of lives

October 15, 2019 Research and Development

A large controlled clinical trial has linked the early use of tranexamic acid to a small fall in the risk …
News
takeda_world

Takeda sheds 30 products in emerging markets in $200m deal

October 15, 2019 Research and Development

Takeda has sold selected prescription and over the counter products to Acino in the Near East, Middle East and Africa …
News
_dsc6538

Medical cannabis: On to greener pastures?

October 14, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …
Feature

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019 Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
News
roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019 Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
News

Three focus areas to accelerate breakthrough drugs to market

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing veeva

The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
Feature
Thought Leadership
jim_greenwood

Biotechnology Innovation Organization Chief to step down after US 2020 elections

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma

The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …
News
top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

It’s the end of the week and time for a rundown of our top most popular articles on Pharmafile these …
News

Bayer UK unveils new Artificial Intelligence ‘LifeHub’

October 10, 2019 Research and Development

Bayer has launched LifeHub UK as part of a network of global innovation hubs designed to accelerate and optimise disease …
News
novo_flag

Novo Nordisk enters into haemophilia gene therapy collaboration

October 10, 2019 Research and Development

Novo Nordisk and bluebird bio have announced they have entered into a three-year research collaboration to jointly develop next-generation in …
News
novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019 Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
News
lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
Feature

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019 Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026